Publications by authors named "D Biasi"
Article Synopsis
- High plasma levels of C5a and C5b-9 indicate complement activation and may serve as important markers for understanding thrombotic antiphospholipid syndrome (APS) during stable disease phases.
- The study compared plasma levels of these markers among three APS patient groups: thrombotic patients responsive to anti-vitamin K (TAPS), refractory thrombosis patients (RAPS), and those with catastrophic APS (CAPS).
- Findings revealed that TAPS patients had significantly lower levels of C5a and C5b-9 compared to RAPS and CAPS patients, suggesting high levels may indicate a more severe disease state and point to a need for enhanced treatment strategies, like complement inhibition, in specific patient subsets.
Secreted Frizzled Receptor Protein 4 (SFRP4) has been shown to be increased in Scleroderma (SSc). To determine its role in immune-driven fibrosis, we analysed SSc and sclerotic Chronic Graft Versus Host Disease (sclGVHD) biosamples; skin biopsies ( = 24) from chronic GVHD patients (8 with and 5 without sclGVHD), 8 from SSc and 3 healthy controls (HC) were analysed by immunofluorescence (IF) and SSc patient sera ( = 77) assessed by ELISA. Epithelial cell lines used for in vitro Epithelial-Mesenchymal-Transition (EMT) assays and analysed by Western Blot, RT-PCR and immunofluorescence.
View Article and Find Full Text PDFProblem: As antiphospholipid antibody-positive women with adverse pregnancy outcomes have higher plasma complement activation product levels, and the placentas of women with antiphospholipid syndrome (APS) exhibit C4d complement component deposition, complement activation involvement has been hypothesized in APS pregnancy complications.
Method Of Study: Plasma levels of C5a and C5b-9 complement components of 43 APS non-pregnant patients and 17 pregnant APS women were measured using enzyme-linked immunosorbent assay. The results were compared with those of 16 healthy non-pregnant women and eight healthy pregnant women, respectively.
Background: Chronic pain is a key symptom in fibromyalgia (FM), and its management is still challenging for rheumatologists in daily practice. FM patients show psychological and psychiatric manifestations, going from mood and emotional disorders to depression and alexithymia that negatively impact their quality of life, limiting their daily activities. Since pharmacological strategies have a limited efficacy in FM pain, alternative or complementary non-pharmacological approaches have been introduced in the clinical management of FM.
View Article and Find Full Text PDF